« Back
Home /
Atorvastatin hemicalcium salt

Atorvastatin hemicalcium salt

€216.00

Excl. VAT

Item no.	HY-17379-200mg
Manufacturer	MedChem Express
CASRN	134523-03-8
Amount	200 mg
Category	Metabolism Cholesterol & Lipid Metabolism Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.93
Formula	C33H34Ca0.5FN2O5
Citations	Cell Death Dis. 2021 May 13;12(5):482. Endocrinology. 2018 May 1;159(5):2008-2021. Front Bioeng Biotechnol. 2022 Mar 17;10:826093. Pharmaceutics. 2022, 14(1), 176. Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. Biomed Pharmacother. 2023 Aug 12;166:115323. Biotechnol Bioeng. 2021 Sep 3. Cancer Lett. 2022 Oct 19;215976. Cell Cycle. 2019 Dec;18(23):3337-3350. Cell Cycle. 2021 Sep 8;1-14. Endocrinology. 2022 May 18;bqac076. Eur J Pharmacol. 2023 Aug 1;956:175938. Eur J Pharmacol. 2023 Dec 21:176261. Exp Cell Res. 2023 Oct 23:113829. Front Cell Dev Biol. 2022 Mar 3;10:806081. Int J Mol Sci. 2023 Apr 19, 24(8), 7492. J Mol Neurosci. 2021 Sep 26. J Nat Prod. 2022 Jun 24. J Neuroimmunol. 2020 Oct 24;350:577429. Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun 8. Oncogene. 2022 Oct 31. Phytomedicine. 2023 Jul 26;119:154997. Proteomics. 2023 May 4;e2300041. Research Square Preprint. 2021 Dec. Research Square Preprint. 2022 Jun. Sci Rep. 2020 Jan 28;10(1):1308. Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [1]Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82. [2]Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22. [3]Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61. [4]Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72. [5] Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821.
Smiles	FC1=CC=C(C2=C(C3=CC=CC=C3)C(C(NC4=CC=CC=C4)=O)=C(C(C)C)N2CC[C@@H](O)C[C@@H](O)CC([O-])=O)C=C1.[0.5Ca2+]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CI-981; Atorvastatin hemicalcium
Available
Product Description	Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
Molecular Weight	577.67
Clinical Information	Launched
Solubility	DMSO : ≥ 50 mg/mL\|H2O : 1 mg/mL (ultrasonic; warming; heat to 60°C)
Pathway	Apoptosis; Autophagy; Metabolic Enzyme/Protease
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-17379-200mg-safety-datasheet.pdf